While there are no Food and Drug Administration (FDA)-approved anti-angiogenic agents for SCCHN, several studies have used VEGF and VEGFR inhibitors in the treatment of SCCHN. This evidence concerns the gene KDR and head and neck squamous cell carcinoma.